Ertugliflozin: Cardioprotective Effects on Epicardial Fat

NCT04167761 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

61

Enrollment

OTHER

Sponsor class

Conditions

Cardiovascular Diseases
Atherosclerosis
Type 2 Diabetes
Insulin Resistance

Interventions

DRUG: Ertugliflozin

Sponsor

Stanford University

Collaborators

[object Object]